Monitor upcoming clinical trial results for EVO756 and EVO301 as these will be key value drivers. Watch for insider trading patterns, particularly from executives with large unvested equity positions. The stock's performance will likely be driven by clinical development milestones rather than financial metrics given the company's pre-revenue status.
Executive Summary
This S-1 filing is a resale registration statement for 4.49 million shares of Evommune (EVMN) being sold by existing investors, including major biotech venture firms. The company will not receive any proceeds from this offering. Evommune is a clinical-stage biotech developing therapies for chronic inflammatory diseases like chronic spontaneous urticaria and atopic dermatitis, with two product candidates in Phase 2 trials. The filing provides financial and operational details required for public trading.
Key Facts
- Resale registration for 4,494,279 shares by selling stockholders; company receives no proceeds
- Company is a clinical-stage biotech developing therapies for chronic inflammatory diseases targeting MRGPRX2 receptor
- Two product candidates (EVO756 and EVO301) in Phase 2 development for conditions including chronic spontaneous urticaria and atopic dermatitis
- No revenue or profitability data disclosed in the filing; company is pre-revenue with no commercial products
- Major investors include LSP, RA Capital, and Pivotal bioVenture, with several board members affiliated with these firms
Financial Impact
No financial impact to company as this is a resale offering with no proceeds to Evommune
Risk Factors
- High risk associated with clinical-stage biotech with no approved products
- Dependence on successful clinical trial outcomes for valuation
- Potential for significant dilution in future capital raises
- Concentration of ownership among venture capital investors who may sell significant portions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001193125-26-161516 |
| Document: d127341dexfilingfees.htm | 0001193125-26-161516 |
| Document: d127341dex51.htm | 0001193125-26-161516 |
| Document: d127341dex231.htm | 0001193125-26-161516 |
| Document: 0001193125-26-161516-index-headers.html | 0001193125-26-161516 |
| Document: 0001193125-26-161516-index.html | 0001193125-26-161516 |
| Document: 0001193125-26-161516.txt | 0001193125-26-161516 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $7.21 | awaiting T+60 | — | $5.16 (−28.43%) |
Sep 15, 2026 6w ago | 8-K | $9.99 | awaiting T+60 | — | $5.16 (−48.35%) |
Jul 30, 2026 12w ago | 8-K | $11.35 $5.10 | ▼ −55.07% | ▼ −57.53% | $5.16 (−54.54%) |
Jul 10, 2026 15w ago | Insider Cluster | $12.10 $6.61 | ▼ −45.37% | ▼ −49.37% | $5.16 (−57.36%) |
Jun 29, 2026 17w ago | 8-K | $15.05 $9.60 | ▲ +36.21% | ▲ +40.60% | $5.16 (+65.71%) |
Jun 24, 2026 17w ago | Insider Cluster | $24.13 $9.65 | ▼ −60.01% | ▼ −63.74% | $5.16 (−78.62%) |
Jun 3, 2026 20w ago | Insider Cluster | $20.69 $13.23 | ▲ +36.06% | ▲ +37.94% | $5.16 (+75.06%) |
Jun 2, 2026 21w ago | 144 | $19.73 $13.48 | ▼ −31.68% | ▼ −34.18% | $5.16 (−73.85%) |
Jun 1, 2026 21w ago | Insider Cluster | $19.82 $14.11 | ▼ −28.81% | ▼ −29.93% | $5.16 (−73.97%) |
May 28, 2026 21w ago | 144 | $23.23 $13.67 | ▲ +41.15% | ▲ +42.34% | $5.16 (+77.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers